Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

Autor: Ewa Janczewska, Beata Dobracka, Dorota Dybowska, Beata Lorenc, Justyna Janocha-Litwin, Łukasz Laurans, Anna Parfieniuk-Kowerda, Jakub Klapaczyński, Robert Flisiak, Piotr M. Stępień, Jerzy Jaroszewicz, Krzysztof Simon, Jolanta Białkowska-Warzecha, Magdalena Tudrujek-Zdunek, Rafał Krygier, Dorota Zarębska-Michaluk, Włodzimierz Mazur, Barbara Sobala-Szczygieł, Łukasz Socha, Waldemar Halota, Małgorzata Pawłowska, Anna Piekarska, Krzysztof Tomasiewicz, Jolanta Citko, Hanna Berak, Marek Sitko
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 3280, p 3280 (2021)
Volume 10
Issue 15
ISSN: 2077-0383
Popis: There is still limited data available from real-world experience studies on the pangenotypic regimens in patients with genotype (GT) 3 hepatitis C virus (HCV) infection and liver cirrhosis. The current study aimed to evaluate the efficacy and safety of pangenotypic regimens in this difficult-to-treat population. A total of 236 patients with mean age 52.3 ± 11.3 years and male predominance (72%) selected from EpiTer-2 database were included in the analysis
72% of them were treatment-naïve. The majority of patients (55%) received the combination of sofosbuvir/velpatasvir (SOF/VEL), 71 without and 58 with ribavirin (RBV), whereas the remaining 107 individuals were assigned to glecaprevir/pibrentasvir (GLE/PIB). The effectiveness of the treatment following GLE/PIB and SOF/VEL regimens (96% and 93%) was higher compared to SOF/VEL + RBV option (79%). The univariate analysis demonstrated the significantly lower sustained virologic response in males, in patients with baseline HCV RNA ≥ 1,000,000 IU/mL, and among those who failed previous DAA-based therapy. The multivariate logistic regression analysis recognized only the male gender and presence of ascites at baseline as the independent factors of non-response to treatment. It should be emphasized that despite the availability of pangenotypic, strong therapeutic options, GT3 infected patients with cirrhosis still remain difficult-to-treat, especially those with hepatic impairment and DAA-experienced.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje